Contact Us Today!

617-523-7900

or Use Our Simple Online Form to Give Us Feedback

We welcome your comments and feedback. Please include contact information if you'd like a response.

Did you find this page helpful?





If you would like a response, please include your contact information.

 

Title
Combination Lucentis and Proton Radiation for Choroidal Melanoma

MEEI Protocol ID

07-06-040

National Clinical Trial (NCT) Number

NCT00765921

Condition

Choroidal Melanoma
Sponsor
Genentech
Principal Investigator
Ivana Kim, M.D.
Study Design
This is a Phase II singel center, masked, randomized clinical trial.
Study Objective
To evaluate the safety of 2 doses of Lucentis,a medication that is anti-angiogenic and anti-inflammatory, in combination with proton radiation for patients with melanoma of the eye.  We will also assess if Lucentis injections may be beneficial for reducting complications due to proton radiation.
Who is Eligible
Individuals with untreated choroidal melanomas that are located near structures that are important for good vision (optic nerve, macula).
Subject Enrollment
We are currently enrolling individuals with eye melanoma who meet all study criteria.
Study Treatment
All qualified participants will receive their first Lucentis injection before they begin a five-day course of proton radiation, which is standard therapy for patients with ocular melanoma.  Subsequently, Lucentis injections will be given every two months for two years.
For More Information
Edward Miretsky, Study Coordinator
617-573-4382

 

 

 

Click here to return to the Ophthalmology Clinical Research page.